<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773886</url>
  </required_header>
  <id_info>
    <org_study_id>MahrishiMU 1012</org_study_id>
    <nct_id>NCT04773886</nct_id>
  </id_info>
  <brief_title>Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine. .</brief_title>
  <official_title>To Evaluate the Effectiveness of Mineral Trioxide Aggregate and Platelet Rich Fibrin Along With Biodentine as Pulpotomy Medicament in Patients With Pulpitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maharishi Markendeswar University (Deemed to be University)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maharishi Markendeswar University (Deemed to be University)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to clinically and radiographically evaluate the effectiveness of&#xD;
      MTA, Biodentine, Platelet Rich Fibrin along with Mineral Trioxide Aggregate and Platelet Rich&#xD;
      Fibrin along with Biodentine as pulpotomy medicament in patients with pulpitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study&#xD;
      based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated&#xD;
      into 4 groups (15 each)&#xD;
&#xD;
      Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as&#xD;
      pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine&#xD;
      as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and&#xD;
      Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP:&#xD;
      Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent Patients were&#xD;
      assessed at 1 day,3 months, 6 months and 9 months postoperatively for pain, pulp sensitivity&#xD;
      test, swelling or presence of any sinus tract. All the proposed teeth were assessed&#xD;
      radiographically at1 day, 3 months, 6 months and 9 months postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sixty systemically healthy patients with irreversible pulpitis were enrolled in the study based on inclusion and exclusion criteria. All the enrolled patients were randomly allocated into 4 groups (15 each)&#xD;
Group I: MTA GROUP: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent. Group II: BIODENTINE GROUP: Vital Pulpotomy will be done using Biodentine as pulp capping agent. Group III: PRF + MTA GROUP: Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent. Group IV: PRF+ BIODENTINE GROUP: Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>patient and statistician are masked about the treatment modality.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>EPT</measure>
    <time_frame>change from baseline to 1day, 3 months, 6 months, 9 months</time_frame>
    <description>Electric pulp testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cold test</measure>
    <time_frame>change from baseline to 1day, 3 months, 6 months, 9 months</time_frame>
    <description>cold test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tender on percussion</measure>
    <time_frame>change from baseline to 1day, 3 months, 6 months, 9 months</time_frame>
    <description>present or absent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>swelling</measure>
    <time_frame>change from baseline to 1day, 3 months, 6 months, 9 months</time_frame>
    <description>present or absent</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pulpitis - Irreversible</condition>
  <arm_group>
    <arm_group_label>MTA GROUP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vital Pulpotomy will be done using Mineral trioxide aggregate(MTA) as pulp capping agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIODENTINE GROUP</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Vital Pulpotomy will be done using Biodentine as pulp capping agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRF + MTA GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vital Pulpotomy will be done using PRF and Mineral trioxide aggregate (MTA) as pulp capping agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRF+ BIODENTINE GROUP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vital Pulpotomy will be done using PRF and Biodentine as pulp capping agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mineral trioxide aggregate</intervention_name>
    <description>Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent</description>
    <arm_group_label>MTA GROUP</arm_group_label>
    <arm_group_label>PRF + MTA GROUP</arm_group_label>
    <other_name>MTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biodentine</intervention_name>
    <description>Vital Pulpotomy will be done using Biodentine as pulp capping agent</description>
    <arm_group_label>BIODENTINE GROUP</arm_group_label>
    <arm_group_label>PRF+ BIODENTINE GROUP</arm_group_label>
    <other_name>Biodenine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet rich fibrin</intervention_name>
    <description>10 ml of blood was drawn from the peripheral vein in the selected patients with the help of sterilized disposable syringe and blood was collected in the pre-sterilized borosilicate glass test tube, without any addition of anticoagulant and was immediately centrifuged at 3000 rpm for 15 minutes in a centrifuge unit.&#xD;
The product obtained after centrifugation consisted of three layers:&#xD;
Acellular platelet plasma- top most layer&#xD;
Platelet rich fibrin -middle layer&#xD;
Red blood corpuscles- bottom layer PRF was then separated from the red blood corpuscles base with the help of sterile tweezers and scissors and squeezed with the help of sterile gauze piece</description>
    <arm_group_label>PRF + MTA GROUP</arm_group_label>
    <arm_group_label>PRF+ BIODENTINE GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with carious exposed tooth exhibiting clinical and radiographical evidence&#xD;
             for pulpitis.&#xD;
&#xD;
          -  Deep caries extending ≥2/3 of dentin.&#xD;
&#xD;
          -  Tooth with positive response with cold testing.&#xD;
&#xD;
          -  Tooth with no mobility.&#xD;
&#xD;
          -  No signs of pulpal necrosis including sinus tract or swelling.&#xD;
&#xD;
          -  Patient approval for the treatment and follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any systemic disease that could influence the outcome.&#xD;
&#xD;
          -  Non-restorable tooth.&#xD;
&#xD;
          -  Teeth with periapical widening.&#xD;
&#xD;
          -  Tooth which cannot be isolated.&#xD;
&#xD;
          -  Teeth with marginal periodontitis or crestal bone loss.&#xD;
&#xD;
          -  Indication of post/ post and core restoration marginal periodontitis with attachment&#xD;
             loss &gt;5mm.&#xD;
&#xD;
          -  Teeth with immature root or calcified canal.&#xD;
&#xD;
          -  Teeth with internal and external resorption.&#xD;
&#xD;
          -  No pulp exposure after caries excavation.&#xD;
&#xD;
          -  Uncontrolled bleeding after access cavity preparation after several minutes N&#xD;
&#xD;
          -  No bleeding at all at the time of access opening&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Individual hypersensitive or allergic to any product used in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>surinder sachdeva, M.D.S.</last_name>
    <role>Study Director</role>
    <affiliation>PROFESSOR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Conservative Dentistry and Endodontics, M.M. College of Dental Sciences and Research.</name>
      <address>
        <city>Ambāla</city>
        <state>Haryana</state>
        <zip>133207</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Li Y, Sui B, Dahl C, Bergeron B, Shipman P, Niu L, Chen J, Tay FR. Pulpotomy for carious pulp exposures in permanent teeth: A systematic review and meta-analysis. J Dent. 2019 May;84:1-8. doi: 10.1016/j.jdent.2019.03.010. Epub 2019 Apr 11.</citation>
    <PMID>30981748</PMID>
  </reference>
  <reference>
    <citation>Kumar V, Juneja R, Duhan J, Sangwan P, Tewari S. Comparative evaluation of platelet-rich fibrin, mineral trioxide aggregate, and calcium hydroxide as pulpotomy agents in permanent molars with irreversible pulpitis: A randomized controlled trial. Contemp Clin Dent. 2016 Oct-Dec;7(4):512-518.</citation>
    <PMID>27994420</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>March 13, 2021</last_update_submitted>
  <last_update_submitted_qc>March 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maharishi Markendeswar University (Deemed to be University)</investigator_affiliation>
    <investigator_full_name>DR SURINDER SACHDEVA</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>pulpal regeneration</keyword>
  <keyword>pulpitis</keyword>
  <keyword>pulpotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

